Results 41 to 50 of about 119,295 (311)

Real-world data analysis of next-generation sequencing and corresponding clinical characteristics in thyroid tumor

Endocrine Connections
Next-generation sequencing (NGS) is of great benefit to clinical practice in terms of identifying genetic alterations. This study aims to clarify the gene background and its influence on thyroid tumors in the Chinese population.
Xu-Feng Chen, Cong He, Peng-Cheng Yu, Wei-Dong Ye, Pei-Zheng Han, Jia-Qian Hu, Yu-Long Wang   +6 more
doaj   +1 more source

Synthesis of potential inhibitors of BRAF V600E

, 2023
reservedSintesi di potenziali inibitori di BRAF V600E derivanti da un pregresso studio di docking. Sono stati sintetizzati diversi analoghi da testare successivamente in vitro per confermarne l'attività inibitoria.
CALZAVARA, ANDREA
core  

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

Thyroid cancer and endocrine disruptive chemicals: a case–control study on per-fluoroalkyl substances and other persistent organic pollutants

European Thyroid Journal
Objective: The aim was to evaluate the possible association between some endocrine disruptive chemicals and thyroid cancer (TC) in an Italian case–control cohort.
Valentina Cirello, Marina Lugaresi, Claudia Moneta, Patrice Dufour, Alessandro Manzo, Erika Carbone, Carla Colombo, Laura Fugazzola, Corinne Charlier, Catherine Pirard   +9 more
doaj   +1 more source

Ameloblastic Fibrosarcoma of the Jaw: Case Report, Genetic Profiling, and Literature Review

Case Reports in Oncology, 2023
Ameloblastic fibrosarcoma (AFS) is considered a malignant progression resulting from dysplastic changes in an ameloblastic fibroma (AF). Both tumors are extremely rare, with only a few cases reported in the scientific literature.
Duna Barakeh, Afaf Alsolami, Malak Abedalthagafi   +2 more
doaj   +1 more source

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma [PDF]

New England Journal of Medicine, 2014
Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations.In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or ...
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandala' M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K   +34 more
openaire   +3 more sources

BRAF V600E mutáció vizsgálata hajas sejtes leukémiában

, 2021
Kutatási munkám célja a BRAF gén V600E mutáció kimutatásának beállítása HRM módszer alkalmazásával. A mutáció kimutatására több módszer is alkalmas, Sanger szekvenálás, allélspecifikus PCR vagy nagy felbontású olvadáspont-analízis.
Kazamér, Barbara
core  

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Agents to treat BRAF-mutant lung cancer

, 2019
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be
Jean G Bustamante Alvarez, Gregory A Otterson   +1 more
core   +1 more source

Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma

, 2022
Background. The treatment and prognosis of metastatic melanoma have changed during the last decade to include immunotherapy or targeted therapy as standard therapeutic options for BRAF-mutated melanoma.
Ondrej Kubecek, Peter Priester, Jindrich Kopecky, Hana Vosmikova, Eva Cermakova, Aneta Kyllarova   +5 more
core   +1 more source